About: Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 28 May 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в травні 2009 (uk) scientific article published on 28 May 2009 (en) مقالة علمية نشرت في 28 مايو 2009 (ar)
publication date	wds:Q37301824-B4611FC8-1BEE-48DF-835C-9A3869E0CA11
publication date	2009-05-28 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37301824-67206E1A-AFE6-4BDA-9038-7E6E3D34B0B6
language of work or name	English
cites work	wds:Q37301824-22081E4E-3121-4AD5-91B5-95CB1E93602C wds:Q37301824-2783BC22-1F93-428C-AC26-575E00B51186 wds:Q37301824-37B739EA-0741-4254-90C6-FF92799A8FC9 wds:Q37301824-CF4D4932-79B3-4843-8585-B4028F04BF8B wds:Q37301824-D8A0C1B2-7B7C-4E33-9D77-FAD48735DC0C wds:Q37301824-FACC19C0-513A-4E8F-A0C6-EEC1CB224F0C
cites work	Tissue plasminogen activator for acute ischemic stroke Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
author name string	wds:Q37301824-616B843D-8DCD-42FC-82BF-DA1C7F4036B2 wds:Q37301824-90754638-1C53-4A5F-AA22-82BDAA49295A
author name string	Erich Bluhmki Vincent N Thijs
rdfs:label	Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (en) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (nl) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (ast)
skos:prefLabel	Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (en) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (nl) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (ast)
name	Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (en) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (nl) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. (ast)
author	wds:Q37301824-AD5893C7-6256-4B5A-82B2-FECFEC7974E8
author	Maarten G. Lansberg
title	wds:Q37301824-293F5A42-1753-4B6C-A3FF-807B89F1532E
title	Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis (en)
page(s)	wds:Q37301824-2BDFEAA7-E635-4B71-8AD5-4B4042E70898
page(s)	2438-2441
instance of	wds:Q37301824-319026D0-AD4F-46A3-8CA6-0C33A43992A1 wds:Q37301824-f4ec1c81-03a9-4973-b8c6-30250890f2ef
instance of	meta-analysis scholarly article
main subject	wds:Q37301824-619F2556-49BB-4B96-BCB5-31572330F35D wds:Q37301824-8546AFC5-9205-408A-B10B-C324F23F7087
main subject	plasminogen meta-analysis
PubMed ID	wds:Q37301824-48F6890B-F2CA-41F7-ACEC-2557FD3522D2
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19478213
PubMed ID	19478213
published in	wds:Q37301824-B874D4E6-3B6D-470C-81EF-CA8532C32BB4
published in	Stroke Journal
issue	wds:Q37301824-DBE3C2C8-F844-4C40-91FC-002B23091654
volume	wds:Q37301824-9663EC8F-7FD8-4141-8877-B69A00CD3021
issue	7
volume	40
DOI	wds:Q37301824-4662793E-B526-4BF7-9AAA-5E5703C49552
DOI	http://dx.doi.org/10.1161/STROKEAHA.109.552547
DOI	10.1161/STROKEAHA.109.552547
PMCID	wds:Q37301824-8FA173FC-0413-4590-B128-4C93EB8E51F6
PMCID	2725521
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37301824
is cites work of	Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Translating promising preclinical neuroprotective therapies to human stroke trials Quality measures in stroke Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death? Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke Implementation of Computerized Physician Order Entry Is Associated With Increased Thrombolytic Administration for Emergency Department Patients With Acute Ischemic Stroke. RIGOR guidelines: escalating STAIR and STEPS for effective translational research The High Cost of Stroke and Stroke Cytoprotection Research. Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Shaping plasticity to enhance recovery after injury Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science Tissue plasminogen activator prevents white matter damage following stroke Electroacupuncture Pretreatment as a Novel Avenue to Protect Brain against Ischemia and Reperfusion Injury Utilization of intravenous thrombolysis is increasing in the United States Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA). Neural bases of recovery after brain injury Mechanical thrombectomy for the treatment of acute ischemic stroke Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator Modulation of brain plasticity in stroke: a novel model for neurorehabilitation Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator. Etiology and treatment of ischaemic stroke in patients with β-thalassemia major.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software